ReachMD’s Post

Updated findings from the phase 2 RAMP 201 study indicate that the combination of avutometinib and defactinib showed positive overall response rates and progression-free survival in recurrent low-grade serous ovarian cancer. #gyncsm https://lnkd.in/ewadWrwh

NICE endorses alectinib for ALK-positive lung cancer, offering a cost-effective, sustainable treatment option that reduces recurrence risk and aligns with NHS goals. #LungCancerTreatment #NICE #HealthcareInnovation #MarketAccessToday #MarketAccess

Worrisome news regarding profound undertreatment of men with metastatic hormone-sensitive prostate cancer. The clinical benefits of innovative therapies in approved and NCCN/AUA/ASCO-recommended regimens cannot be translated in enhancement of longevity and well-being of candidate patients if the latter never receive such therapies... A triplet regimen has been established as ths tandard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nonetheless, a recent survey of physician practices reveals that a mere one-third of patients receive first-line treatment intensification with an androgen receptor pathway inhibitor and/or docetaxel. This is unacceptable as we are crossing into the 2nd quarter of the 21st century. This should be a clarion call to increase access to therapies across the #prostatecancer care ecosystem. https://lnkd.in/e547WFZP

Research from the phase 3 KEYNOTE 868/NRG-GY018 study, presented at an MSD Korea seminar, indicates promising responses to combining #Keytruda (pembrolizumab) with carboplatin and paclitaxel for treating advanced or recurrent endometrial cancer, although high costs and slow insurance coverage remain significant barriers to patient access. https://lnkd.in/ghZ6DMp2

🎉 So thrilled to see Patient Navigation as "cost-effective" for CRC Screening!! 🚀🩺 The Community Preventive Services Task Force (CPSTF) finds patient navigation services increase colorectal cancer screening AND are cost-effective! 💸💯 Plus, the return on investment is favorable, with colonoscopy reimbursement values exceeding the cost of the intervention. 🏆📈 #Healthcare #ColorectalCancer #CostEffective #PatientNavigation #ACSNNRT https://lnkd.in/ePkFUwWF

APAC is the hot bed for HCC…with 80% of the worlds diagnosis and a need to improve mortality rates. Early diagnosis always helps…but is very difficult to do effectively and stay affordable. Tackling this problem is the AHCC - a clinical trial group consisting of 62 pioneering clinical Centres. Their work is showcased here. #oncology #clinicaltrials #oncoshot #oncopericia #cancercare #cancerresearch

Prostate, kidney, and bladder cancers rank among the top ten newly diagnosed cancers, yet clinical trials for these diseases often lack adequate representation. How does this affect patient care, and what can we do about it? Join us in exploring the critical gaps in GU cancer clinical trials, from race and ethnicity to age and sex. Addressing these gaps is crucial for ensuring that clinical trial results are generalizable and beneficial to all patients. Without adequate representation, we miss critical insights into how different demographic groups respond to treatments, potentially compromising the effectiveness and safety of therapies across the board. Explore the path to more inclusive trials and better patient outcomes: https://ow.ly/T67A50SK5Hp #Oncology #GenitourinaryCancer #CancerResearch #HealthEquity #PatientCare

In the fight against liver cancer, acting at the right moment makes all the difference. Early detection can profoundly impact survival rates and open doors to more treatment options. By staying aware of the early signs and prioritizing regular screenings, we can give ourselves and our loved ones a stronger chance for a healthier, brighter future. Read on to know more. https://lnkd.in/g2J2hema #livercancerawarenessmonth #AmericanOncologyInstitute #AOICancerCare #WeJourneyWithYou

Exciting news in colorectal cancer treatment: AOTMiT President endorses Lonsurf, offering new hope and options for patients and healthcare providers. #RegulatoryAgencies #HealthcareInnovation #PricingandReimbursement #CancerTreatment #Publications #MarketAccessToday #MarketAccess

A recent article in Healthcare Business Today, authored by our CEO, Dr. Raghav Murali-Ganesh. Value-Based Care is a widely used term in the healthcare industry, so lets unpack the practical application in oncology. What are the different levers, and when should they be employed? In this article Raghav describes the landscape of oncology and healthcare from both the perspective of an oncologist and as the CEO/Co-Founder of Osara Health. #valuebasedcare #oncology #behaviorchange